Microba Life Sciences Ltd
ASX:MAP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.15
0.215
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Microba Life Sciences Ltd
Cash from Financing Activities
Microba Life Sciences Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Microba Life Sciences Ltd
ASX:MAP
|
Cash from Financing Activities
AU$18.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Sonic Healthcare Ltd
ASX:SHL
|
Cash from Financing Activities
AU$592.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Integral Diagnostics Ltd
ASX:IDX
|
Cash from Financing Activities
-AU$29.5m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Capitol Health Ltd
ASX:CAJ
|
Cash from Financing Activities
-AU$12.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
Australian Clinical Labs Ltd
ASX:ACL
|
Cash from Financing Activities
-AU$146.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Healius Ltd
ASX:HLS
|
Cash from Financing Activities
-AU$259m
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-13%
|
|
Microba Life Sciences Ltd
Glance View
Microba Life Sciences is a precision microbiome science company powering medical innovation to transform human health. The company is headquartered in Brisbane, Queensland. The company went IPO on 2022-04-05. The firm specializes in the analysis of gut microbiome and promotes development in pathology services, therapeutics and diagnostics based on the microbiome. The firm's flagship product is the Microba Insight, a sampling kit that allows the public to analyze personal gut microbiome. Its discovery platform uses human data and informatic approaches to connect microbial genotype to human phenotype. The company also offers support solutions to researchers.
See Also
What is Microba Life Sciences Ltd's Cash from Financing Activities?
Cash from Financing Activities
18.4m
AUD
Based on the financial report for Jun 30, 2024, Microba Life Sciences Ltd's Cash from Financing Activities amounts to 18.4m AUD.
What is Microba Life Sciences Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
6%
Over the last year, the Cash from Financing Activities growth was 10%. The average annual Cash from Financing Activities growth rates for Microba Life Sciences Ltd have been 10% over the past three years , 6% over the past five years .
You don't have any saved screeners yet